459 related articles for article (PubMed ID: 32144135)
1. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
[TBL] [Abstract][Full Text] [Related]
2. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
3. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
4. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.
de Rosa N; Rodriguez-Bigas MA; Chang GJ; Veerapong J; Borras E; Krishnan S; Bednarski B; Messick CA; Skibber JM; Feig BW; Lynch PM; Vilar E; You YN
J Clin Oncol; 2016 Sep; 34(25):3039-46. PubMed ID: 27432916
[TBL] [Abstract][Full Text] [Related]
5. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
7. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
[TBL] [Abstract][Full Text] [Related]
8. Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Meillan N; Vernerey D; Lefèvre JH; Manceau G; Svrcek M; Augustin J; Fléjou JF; Lascols O; Simon JM; Cohen R; Maingon P; Bachet JB; Huguet F
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):824-833. PubMed ID: 31404579
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
10. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
12. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients.
Ni K; Zhan Y; Liu Z; Zhao XZ; Wang W; Wang G; Zhang Z; Li G; Zhang X; Zhang C
J Surg Oncol; 2022 Mar; 125(4):692-702. PubMed ID: 34918842
[TBL] [Abstract][Full Text] [Related]
13. DNA Mismatch Repair-deficient Rectal Cancer Is Frequently Associated With Lynch Syndrome and With Poor Response to Neoadjuvant Therapy.
Farchoukh LF; Celebrezze J; Medich D; Cunningham K; Holder-Murray J; Holtzman M; Lee K; Choudry H; Pai RK
Am J Surg Pathol; 2022 Sep; 46(9):1260-1268. PubMed ID: 35551135
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
15. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
[No Abstract] [Full Text] [Related]
17. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
Sargent DJ; Marsoni S; Monges G; Thibodeau SN; Labianca R; Hamilton SR; French AJ; Kabat B; Foster NR; Torri V; Ribic C; Grothey A; Moore M; Zaniboni A; Seitz JF; Sinicrope F; Gallinger S
J Clin Oncol; 2010 Jul; 28(20):3219-26. PubMed ID: 20498393
[TBL] [Abstract][Full Text] [Related]
18. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
Clay MR; Allison KH; Folkins AK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
[TBL] [Abstract][Full Text] [Related]
19. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
[No Abstract] [Full Text] [Related]
20. The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.
Wu Z; Hu H; Wang C; Zhang J; Cai Y; Xie X; Huang Y; Deng Y
Ann Transl Med; 2022 Apr; 10(8):491. PubMed ID: 35571401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
